Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

ACCC sent a letter to House and Senate leaders this week, encouraging Congress to take action before the end of this year to mitigate significant Medicare payment cuts and improve patient access to high quality, efficient, and equitable cancer care. Without congressional intervention, significant reductions to Medicare payment will take effect in January 2023, including the proposed 4.42% reduction …
In recognition of Pharmacy Technician Day today (October 18), ACCCBuzz spoke with Danielle Duy, CPhT, to learn more about her role on the multidisciplinary cancer care team.
Learn more about how this health system is gleaning new insights into clinical workforce needs to optimize future staffing and scheduling decisions.
Awards recognize significant contributions to oncology care ROCKVILLE, MD – The Association of Community Cancer Centers (ACCC) today announced the 2022 Annual Award recipients at the ACCC 39th Annual National Oncology Conference. Oncology leaders across the country are convening this week at the association’s national conference to discuss innovation and ways to create positive change among …
In this episode, Dr. Noel breaks down how to build trust and earn the respect of under-represented patient populations in the community.
Healthcare—especially oncology—is rife with competing demands that make it particularly challenging to engage oncology staff in innovation. #ACCCNOC keynote speaker Julie Holmes shares her principles for innovating in healthcare through “little big bangs” (or micro-innovations).
Created to address burnout and improve retention rates, Medstar's Regional Staff Support Program provides staff with an opportunity to participate in monthly employee celebrations, encourages peer-to-peer recognition, and enhances communication among associates.
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Imfinzi® (durvalumab) – AstraZeneca’s PD-L1 inhibitor was newly approved for use, in combination with gemcitabine and cisplatin, as treatment for adult patients with locally advanced or metastatic biliary tract cancer (BTC). The expansion beyond lung cancer—where the IO agent …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Imfinzi® (durvalumab) – AstraZeneca’s PD-L1 inhibitor was newly approved for use, in combination with gemcitabine and cisplatin, as treatment for adult patients with locally advanced or metastatic biliary tract cancer (BTC). The expansion beyond lung cancer—where the IO agent …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Imfinzi® (durvalumab) – AstraZeneca’s PD-L1 inhibitor was newly approved for use, in combination with gemcitabine and cisplatin, as treatment for adult patients with locally advanced or metastatic biliary tract cancer (BTC). The expansion beyond lung cancer—where the IO agent …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Imfinzi® (durvalumab) – AstraZeneca’s PD-L1 inhibitor was newly approved for use, in combination with gemcitabine and cisplatin, as treatment for adult patients with locally advanced or metastatic biliary tract cancer (BTC). The expansion beyond lung cancer—where the IO agent …
PowerPoint Presentation Oct. 13, 2022 TxSCO Update Overview: Notable Updates 2 Federal • Provider reimbursement • Bill to Prevent Pay Cut Introduced in the House • White Bagging update • 340B • Recent scrutiny • CMMI EOM • The Latest State • Select Committee on Health Care Reform • Texas Palliative Care Interdisciplinary Advisory Council …
WEST PALM BEACH, FL – The Association of Community Cancer Centers (ACCC) today announced the winning programs for its 12th annual ACCC Innovator Awards, highlighting the year’s leading-edge solutions to improve cancer care delivery and the patient experience. The 2022 ACCC Innovator Award recipients each delivered a presentation to their oncology care colleagues from across the country, gathering this …
The ACCC 39th National Oncology Conference opened with two pre-conferences, covering financial advocacy in oncology and the future of cancer care. Learn what care delivery may look like in 2040 and how ACCC is supporting cancer programs and practices through its Financial Advocacy Network.
When updating the Financial Advocacy Services Guidelines, the ACCC Financial Advocacy Network engages key stakeholders to ensure a collaborative, consensus-based process, gaining buy-in across the oncology community.
OUR MISSION: NEVADA ONCOLOGY SOCIETY 1801 Research Boulevard, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.nos-nevada.com Oncology State Societies at ACCC Engage & Succeed. APPLICATION FOR MEMBERSHIP Annual membership dues (July 1–June 30) must accompany application. Mail payment with this form to: Nevada Oncology Society; 1801 Research …
OUR MISSION: THE ARIZONA CLINICAL ONCOLOGY SOCIETY 1801 Research Boulevard, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.tacos-oncology.com Oncology State Societies at ACCC Engage & Succeed. APPLICATION FOR MEMBERSHIP Annual membership dues (July 1–June 30) must accompany application. Mail payment with this form to: The Arizona Clinical …
OUR MISSION: Oncology State Societies at ACCC Engage & Succeed. EMPIRE STATE HEMATOLOGY & ONCOLOGY SOCIETY 1801 Research Blvd, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.eshos-ny.com APPLICATION FOR MEMBERSHIP Annual membership dues (July 1–June 30) must accompany application. Mail payment with this form to: Empire …
OUR MISSION: MINNESOTA SOCIETY OF CLINICAL ONCOLOGY 1801 Research Boulevard, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.msco-minnesota.com Oncology State Societies at ACCC Engage & Succeed. APPLICATION FOR MEMBERSHIP Annual membership dues (July 1–June 30) must accompany application. Mail payment with this form to: Minnesota Society …